FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385972277> ?p ?o ?g. }

• W4385972277 abstract "Abstract Background The efficacy of subsequent therapy after poly-ADP-ribose polymerase (PARP) inhibitor maintenance treatment has raised concerns. Retrospective studies show worse outcomes for platinum-based chemotherapy after progression of PARP inhibitor-maintenance therapy, especially in BRCA-mutant patients. We aimed to describe subsequent therapy in ovarian cancer patients after PARP inhibitor-maintenance therapy and evaluate their response to treatment. We focused on chemotherapy for patients with a progression-free interval (PFI) of ≥ 6 months after prior platinum treatment, based on BRCA status. Methods We analyzed real-world data from Peking University Cancer Hospital, including patients who received subsequent therapy after progression to PARP inhibitor-maintenance therapy for epithelial ovarian cancer between January 2016 and December 2022. Clinicopathological characteristics and treatment outcomes were extracted from medical records. The last follow-up was in May 2023. Results A total of 102 patients were included, of which 29 (28.4%) had a germline BRCA1/2 mutation and 73 (71.6%) exhibited BRCA1/2 wild-type mutations. The PARP inhibitors used were Olaparib (n = 62, 60.8%), Niraparib (n = 35, 34.3%), and others (n = 5, 4.9%). The overall response rate (ORR) was 41.2%, and the median time to second progression (mTTSP) was 8.1 months (95%CI 5.8–10.2). Of 91 platinum-sensitive patients (PFI ≥ 6 months) after progression to PARP inhibitor-maintenance therapy, 65 patients subsequently received platinum regimens. Among them, 30 had received one line of chemotherapy before PARP inhibitor-maintenance therapy. Analysis of these 30 patients by BRCA status showed an ORR of 16.7% versus 33.3% and mTTSP of 7.1 (95% CI 4.9–9.1) versus 6.2 months (95% CI 3.7–8.3, P = 0.550), for BRCA-mutant and wild-type patients, respectively. For the remaining 35 patients who had received two or more lines of chemotherapy before PARP inhibitor-maintenance therapy, ORR was 57.1% versus 42.9%, and mTTSP was 18.0 (95% CI 5.0–31.0) versus 8.0 months (95% CI 4.9–11.1, P = 0.199), for BRCA-mutant and wild-type patients, respectively. Conclusion No differences in survival outcomes were observed among patients with different BRCA statuses. Furthermore, for patients who had undergone two or more lines of chemotherapy before PARP inhibitor maintenance therapy, no negative effects of PARP inhibitors on subsequent treatment were found, regardless of BRCA status." @default.
• W4385972277 created "2023-08-19" @default.
• W4385972277 creator A5009318195 @default.
• W4385972277 creator A5024139201 @default.
• W4385972277 creator A5029028991 @default.
• W4385972277 creator A5029875140 @default.
• W4385972277 creator A5040988832 @default.
• W4385972277 creator A5088829354 @default.
• W4385972277 date "2023-08-18" @default.
• W4385972277 modified "2023-10-12" @default.
• W4385972277 title "A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy" @default.
• W4385972277 cites W2020713814 @default.
• W4385972277 cites W2123696077 @default.
• W4385972277 cites W2151050516 @default.
• W4385972277 cites W2528228811 @default.
• W4385972277 cites W2605456582 @default.
• W4385972277 cites W2737389832 @default.
• W4385972277 cites W2748207273 @default.
• W4385972277 cites W2754327139 @default.
• W4385972277 cites W2897430921 @default.
• W4385972277 cites W2975141952 @default.
• W4385972277 cites W2985223161 @default.
• W4385972277 cites W2994977341 @default.
• W4385972277 cites W3159284264 @default.
• W4385972277 cites W4280571223 @default.
• W4385972277 cites W4283775908 @default.
• W4385972277 cites W4295560660 @default.
• W4385972277 cites W4308548735 @default.
• W4385972277 doi "https://doi.org/10.21203/rs.3.rs-3261346/v1" @default.
• W4385972277 hasPublicationYear "2023" @default.
• W4385972277 type Work @default.
• W4385972277 citedByCount "0" @default.
• W4385972277 crossrefType "posted-content" @default.
• W4385972277 hasAuthorship W4385972277A5009318195 @default.
• W4385972277 hasAuthorship W4385972277A5024139201 @default.
• W4385972277 hasAuthorship W4385972277A5029028991 @default.
• W4385972277 hasAuthorship W4385972277A5029875140 @default.
• W4385972277 hasAuthorship W4385972277A5040988832 @default.
• W4385972277 hasAuthorship W4385972277A5088829354 @default.
• W4385972277 hasBestOaLocation W43859722771 @default.
• W4385972277 hasConcept C104317684 @default.
• W4385972277 hasConcept C121608353 @default.
• W4385972277 hasConcept C126322002 @default.
• W4385972277 hasConcept C143998085 @default.
• W4385972277 hasConcept C182979987 @default.
• W4385972277 hasConcept C2776694085 @default.
• W4385972277 hasConcept C2778283404 @default.
• W4385972277 hasConcept C2779138821 @default.
• W4385972277 hasConcept C2779962180 @default.
• W4385972277 hasConcept C2780194787 @default.
• W4385972277 hasConcept C2780427987 @default.
• W4385972277 hasConcept C55493867 @default.
• W4385972277 hasConcept C71924100 @default.
• W4385972277 hasConcept C82381507 @default.
• W4385972277 hasConcept C86803240 @default.
• W4385972277 hasConceptScore W4385972277C104317684 @default.
• W4385972277 hasConceptScore W4385972277C121608353 @default.
• W4385972277 hasConceptScore W4385972277C126322002 @default.
• W4385972277 hasConceptScore W4385972277C143998085 @default.
• W4385972277 hasConceptScore W4385972277C182979987 @default.
• W4385972277 hasConceptScore W4385972277C2776694085 @default.
• W4385972277 hasConceptScore W4385972277C2778283404 @default.
• W4385972277 hasConceptScore W4385972277C2779138821 @default.
• W4385972277 hasConceptScore W4385972277C2779962180 @default.
• W4385972277 hasConceptScore W4385972277C2780194787 @default.
• W4385972277 hasConceptScore W4385972277C2780427987 @default.
• W4385972277 hasConceptScore W4385972277C55493867 @default.
• W4385972277 hasConceptScore W4385972277C71924100 @default.
• W4385972277 hasConceptScore W4385972277C82381507 @default.
• W4385972277 hasConceptScore W4385972277C86803240 @default.
• W4385972277 hasLocation W43859722771 @default.
• W4385972277 hasOpenAccess W4385972277 @default.
• W4385972277 hasPrimaryLocation W43859722771 @default.
• W4385972277 hasRelatedWork W1990291556 @default.
• W4385972277 hasRelatedWork W2164296043 @default.
• W4385972277 hasRelatedWork W2345680184 @default.
• W4385972277 hasRelatedWork W2531990663 @default.
• W4385972277 hasRelatedWork W2741687836 @default.
• W4385972277 hasRelatedWork W2772115384 @default.
• W4385972277 hasRelatedWork W2891585716 @default.
• W4385972277 hasRelatedWork W2947259848 @default.
• W4385972277 hasRelatedWork W3075060969 @default.
• W4385972277 hasRelatedWork W4385446207 @default.
• W4385972277 isParatext "false" @default.
• W4385972277 isRetracted "false" @default.
• W4385972277 workType "article" @default.